Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

The WIN Consortium and New York University Cancer Institute Collaborate

Published: Tuesday, February 12, 2013
Last Updated: Tuesday, February 12, 2013
Bookmark and Share
The Worldwide Innovative Network (WIN) in personalized cancer medicine Consortium is proud to announce that New York University Cancer Institute has joined as a member of the Consortium.

This new partnership will ensure that NYU Cancer Institute play an active and vital role in WIN’s efforts to translate the most innovative approaches in personalized cancer medicine into patient care worldwide. NYU Cancer Institute is an NCI-designated Comprehensive Cancer Center for more than 33 years, a prestigious ranking conferred to select institutions characterized by scientific excellence, the capability to integrate a diversity of research approaches, and leadership in NCI-funded research efforts.

The WIN Consortium was created to spur collaboration between all stakeholders in personalized cancer medicine and to carry out cross-sector, worldwide clinical trials through the Consortium’s global network of academic and industry partners. With significant ongoing oncologic clinical trials, established multidisciplinary research structures, and a track record of successful research partnerships, NYU Cancer Institute is poised to play an integral role in the Consortium.

“NYU Cancer Institute joining WIN is an important step in the continued development of the Consortium’s capabilities and potential,” stated WIN Consortium Chairman Dr. John Mendelsohn. “The clear strengths NYU brings – experience serving a diverse patient population, excellence in disease-focused and basic science research, and committed, involved leadership – will help speed the translation of personalized cancer medicine innovations into the treatment of cancer patients.”

Dr. William Carroll, Director of the NYU Cancer Institute, noted, “This partnership will provide increased opportunities for the NYU Cancer Institute to play a strong role in innovative, global clinical trials and projects. We believe that this collaboration is strategically significant to advancing the practice of personalized cancer medicine and we look forward to active participation in the Consortium.”

Founded in 2010 on the recognition that greater success can be achieved through collaboration than any organization can achieve alone, the WIN Consortium is a global network of 29 leading academic, pharmaceutical, biotech, healthcare IT, and patient advocacy organizations working to accelerate the pace and reduce the cost of translating the most promising advances in genomic-based cancer research into the standard of patient care worldwide. WIN is a non-governmental, not-for-profit organization headquartered in Paris.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
Genetic Signature Linked to Cancer Prognosis Identified
The results of the analysis of 8,161 tissue samples could in the future help clinicians decide how best to treat a patient as well as aid the development of new targeted treatments.
NIH Commits $6.7 M to Advance DNA, RNA Sequencing Technology
"Can you believe they make DNA sequencers the size of staplers?" asked Meni Wanunu, Ph.D. "Ideas that were crazy twenty years ago are now happening!"
Curcumin Shows Promise as Cancer Treatment
When delivered at the correct circadian phase, curcumin demonstrates sustained toxicity in cancer cells and should be considered for use in patient care.
"Junk" DNA Critical for Heart Function
Loss of noncoding elements of genome, known as enhancers, results in abnormalities of heart functions.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos